<DOC>
	<DOCNO>NCT00521859</DOCNO>
	<brief_summary>Primary : Define maximal tolerate dose ( MTD ) VNP40401M give hematopoietic cell transplantation ( HCT ) Secondary : - Describe change pharmacokinetic ( PK ) parameter increase dos drug . - Describe estimate frequency &gt; Grade 3 non-hematologic/non-infectious toxicity MTD . - Report efficacy regimen . - Evaluate rate engraftment regimen .</brief_summary>
	<brief_title>Cloretazine ( VNP40101M ) With Hematopoietic Cell Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>An autologous transplant use recipient 's stem cell , blood bone marrow , infusion . VNP40101M chemotherapy drug design interfere growth development cancer cell , bind structure within cancer cell . This drug , give high dos , cause lower blood cell . Chemotherapy commonly give patient stem cell transplantation help kill cancer cell . After receive drug , stem cell transfuse ( give gradually ) allow re-growth blood cell . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You blood draw ( 3 tablespoon ) routine test . You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . You bone marrow biopsy . To collect bone marrow biopsy , area hip chest bone numb anesthetic , small amount marrow bone withdrawn large needle . You chest x-ray compute tomography ( CT ) positron emission tomography ( PET ) scan , require , measure tumor . You lung function test electrocardiogram ( ECGâ€”a test measure electrical activity heart ) . Women able child must negative blood urine pregnancy test . If blood pregnancy test do routine blood test . Before receive treatment study , apheresis do collect stem cell . Apheresis process remove part blood ( platelet white blood cell ) body order remove certain element , stem cell . Then rest blood return back body . Your stem cell put back body finish treatment VNP40101M . Apheresis do major vein central venous catheter ( CVC ) , usually chest . A CVC sterile flexible tube place large vein local anesthesia . The detail apheresis well CVC describe separate consent form . Your doctor explain procedure detail , require sign separate consent form procedure . If find eligible take part study , receive dose VNP40101M . The dose receive depend enrol study . The dose receive remain throughout study . Researchers continue enroll patient next high dose level high tolerable dose find . About 1 week stem cell collect , admitted hospital . You stay hospital 3 week . You receive VNP40101M CVC 6 hour . Two day receive VNP40101M , autologous stem cell ( blood bone marrow ) give CVC . You receive G-CSF injection skin daily , start 1 week transplantation , help blood cell level return normal . You blood draw ( 5 tablespoon ) PK test measure level VNP40101M blood . These sample draw heparin lock , place 24 hour study treatment complete . A heparin lock small tube connect CVC vein arm easy access . The heparin lock remove sample receive . After release hospital , require stay Houston area 1 month transplantation longer experience intolerable side effect . You ask return M. D. Anderson 2-4 month follow transplantation late side effect study drug observe . As part standard care , blood test ( 3 tablespoon ) routine test . Your health status followed-up continue check status disease . You compute tomography scan PET scan . You also bone marrow biopsy . If disease get bad experience intolerable side effect , take study . THIS IS AN INVESTIGATIONAL STUDY . VNP40101M FDA approve commercially available . It authorize use research . Up 42 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Age 18 65 year autotransplant patient age 18 60 year allotransplant patient . 2 . Patients acute leukemia/MDS lymphoid malignancy , include Hodgkin 's nonHodgkin 's lymphoma ( primary refractory refractory relapse ) , multiple myeloma ( beyond first remission unresponsive therapy ) , qualify treatment protocols high priority . 3 . Adequate renal function , define serum creatinine &lt; 1.5 mg/dL . 4 . Adequate hepatic function , define SGPT &lt; 3 X upper limit normal ; serum bilirubin alkaline phosphatase &lt; 2 X upper limit normal , consider attributable liver disease case alkaline phosphatase . 5 . Adequate pulmonary function FEV1 , FVC DLCO &gt; 50 % expect corrected hemoglobin . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Zubrod performance status &lt; 2 8 . Patients receive allogeneic transplant must relate unrelated donor meet departmental standard donor selection . 1 . Uncontrolled lifethreatening infection 2 . HIV positive 3 . A positive Beta HCG woman child bear potential define postmenopausal 12 month previous surgical sterilization procedure . 4 . Any CNS involvement control least 4 week 5 . Patients must least 21 day prior systemic therapy malignancy , improvement reversible toxicity &lt; /= grade 2 , whichever occur first . 6 . Any patient receiving Antabuse 7 . Patients metronidazole ( Flagyl ) least 24 hour prior start VNP40401M</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Hematopoietic Cell Transplantation</keyword>
	<keyword>Cloretazine</keyword>
	<keyword>VNP40101M</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>